F.P. Journe Watch Fetches $238,400 At Sotheby's ‘Area_51' Auction
The F.P. Journe Chronomètre Bleu Byblos, circa 2015, a limited edition tantalum semi-skeletonized watch was the top lot in a special UFO-themed auction held by Sotheby's in Geneva, titled 'Area_51.' It fetched 203,200 Swiss Francs ($238,425).
The web-like blue and gold dial is housed in a 40mm case made of tantalum, a very hard, ductile, lustrous, blue-gray transition metal that is highly corrosion-resistant. It is powered by the 1304 manual winding caliber.
The watch was one of 51 lots in the sale held at Salle Trocmé, an event space in the city. The live auction held April 3 totaled 1.4 million Swiss francs (more than $1.6 million) with 42 of the 51 lots sold.
The Toledano & Chan b-2 Prototype, created for the Area_51 auction sold for 20,320 CHF
The watches represent the latter half of the 20th century into the present day. The majority of the watches were from the 1960s and '70s, however, there were plenty more recent models and two new watches created for the event: A Furlan Marri piece that is a unique variation of its Disco Volante series that features a tantalum case, marking the first time the brand used this metal. It fetched 16,510 Swiss francs ($19,370), besting its high estimate. The other piece is a Toledano & Chan watch with a unique take on its trademark architectural watch designs. It fetched 20,320 Swiss francs ($23,843), well above its high estimate.
Other top lots in the sale are as follows:
Cartier Crash '13 Rue de la Paix' sold for 186,839 CHF
A Cartier Crash '13 Rue de la Paix', Reference 2774, a limited edition white gold and diamond-set wristwatch, circa 2006. It fetched 165,100 Swiss francs ($193,720).
Gérald Genta platinum and diamond-set minute repeating wristwatch sold for 127,000 CHF
A Gérald Genta reference G.4036, circa 1990, a unique platinum and diamond-set minute repeating wristwatch with bracelet and mother-of-pearl dial. It fetched 127,000 Swiss francs ($149,000).
Audemars Piguet Concept CW1 sold for 114,300 CHF
An Audemars Piguet Royal Oak Concept 'CW1,' Reference 25980AI.OO.D003SU.01. A limited edition alacrite and titanium tourbillon wristwatch with power reserve indicator, dynamograph and function selector, circa 2005.
Buyers from Europe represented half of all the buyers in the sale, followed by buyers from the USA (23%), Asia (19%), Middle East (8%).
The auction followed an exhibition of the pieces culminating in a party held at Salle Trocmé on April 2 where all the 51 watches were on display in a room filled with artificial smoke, lighting and music that evokes the UFO theme of the sale. Many of the watches were displayed under a plastic canopy.
Sotheby's auctioneer Jonny Fowle during the Sotheby's Area_51 live sale showcasing UFO-like ... More avant-garde vintage Watches
This is the second consecutive year Sotheby's Geneva is holding a special thematic auction of watches in collaboration with the creative watch collective, heist-out.
The sale coincides with the Watches and Wonders horology fair in Geneva, held April 1 -7.
The latest event follows 'Rough Diamonds,' an exhibition and auction of unconventional avant-garde timepieces held in April 2024 inside a wine cave in Geneva, also during Watches and Wonders.
Both sales by Sotheby's were in collaboration with heist-out, a Geneva-based creative agency specializing in watchmaking, founded by Maxime Couturier and Lorenzo Maillard. The idea of these thematic sales is to attract younger collectors to auctions. It seems to be having a positive effect as Sotheby's says that nearly a third of all buyers participating in the sale were under 40 and 26% were new to Sotheby's.
'This year the activation was even more ambitious, offering watch lovers and collectors alike pieces inspired by outer space or as unique as UFOs,' said Manon Hagie, head of Sale for Area_51. 'The theme clearly chimed with dozens of international committed bidders, with nearly forty per cent of them bidding from the USA, despite the uncertainty about newly announced tariffs. A sign that the market is continuing to show some resistance to risk when the watches are truly exceptional.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vf
Yahoo
6 hours ago
- Yahoo
Nestle unveils method to boost cocoa yields as climate change hits
Faced with climate change diminishing farmers' yields, Nestle announced Wednesday that it was working on a technique to produce chocolate by using up to 30 percent more of the cocoa fruit. Chocolate is traditionally made using only cocoa beans taken from inside the pod, meaning that a large amount of the fruit -- including the pulp, placenta and pod husk -- "remains largely unused", the Swiss food giant said. Its researchers have "developed a patented technique that leverages all parts of the fruit inside the cocoa pod", it said. Everything inside the pod is collected as a wet mass that then ferments naturally, "unlocking the key chocolate flavour", Nestle said. "The mass is then ground, roasted and dried into chocolate flakes which can be used to make chocolate without compromising the taste." Nestle said the approach cut down on waste while helping farmers get more yield and value. "With climate change increasingly affecting cocoa yields around the world, we are exploring innovative solutions that could help cocoa farmers maximise the potential of their harvests," said Louise Barrett, head of the Nestle research and development centre for confectionery in York, England. "While this project is still at a pilot stage, we are currently exploring how to apply this innovation at a larger scale," she said. - Heat takes toll - Cocoa prices had been stable for around 10 years but began to soar in early 2023. A tonne of cocoa was worth £1,900 ($2,560) on the London commodities market in January 2023, shot up to £3,800 a year later, and reached a high of over £9,000 last December. The surge was the result of poor harvests in the leading producers Ivory Coast and Ghana, as unusually heavy rains, a cocoa pod disease outbreak and then drought took their toll. In February, a study by the Climate Central research group found that "excessive heat can contribute to a reduction in the quantity and quality of the harvest" for cocoa growers. The report calculated that over the last decade, climate change had added an extra three weeks of above 32C in Ivory Coast and Ghana during the main growing season from October to March -- above the levels considered optimum for cacao trees. The surge in prices dampened demand while also pushing farmers to devote more resources to cocoa cultivation. That allowed prices to ease in recent months, with reserves being built up for the first time in four years. Since the beginning of 2025, prices have declined, and a tonne was worth around £5,600 on Wednesday. vog/rjm/js
CNBC
7 hours ago
- CNBC
Stocks making the biggest premarket moves: Target, Lowe's, Snowflake and more
Check out the companies making the biggest moves in premarket trading: Target — The big box retailer sank 10.5% after announcing CEO Brian Cornell will be replaced by Chief Operating Officer Michael Fiddelke on Feb.1. Target also posted a second-quarter earnings and revenue beat, although its sales and traffic declined, and reiterated its full-year outlook. Lowe's — Shares of the home improvement retailer moved 3% higher on the back of its latest financial results . Earnings came in at $4.33 per share for the second quarter, topping the $4.24 expected from analysts polled by LSEG. Revenue was $23.96 billion, matching the consensus estimate. Lowe's also increased its full-year sales guidance. Estée Lauder — Shares tumbled 8% after the beauty company said it expects tariff-related headwinds to impact profitability for its fiscal 2026 year by approximately $100 million. Estée Lauder also guided for fiscal 2026 adjusted earnings per share in a range below FactSet's consensus estimate, and for fiscal 2026 year-over-year revenue growth of 2.5%, less than the expected 2.6%. Hertz — The car rental company jumped 9% after announcing it will begin selling pre-owned vehicles on Amazon Autos. The offering will be available beginning in four city areas as soon as Wednesday and will expand to 45 locations nationwide. Analog Devices — The stock rose 3.8% following the semiconductor company's earnings beat. Analog Devices reported third-quarter adjusted earnings of $2.05 per share on revenues of $2.88 billion. Analysts polled by LSEG had expected EPS of $1.95 on revenues of $2.77 billion. The company also raised its fourth-quarter guidance. TJX — The stock rose 4.4% after the discount retailer reported second-quarter results that exceeded expectations. TJX posted earnings of $1.10 per share on revenues of $14.40 billion. Analysts polled by LSEG had expected per-share earnings of $1.01 on revenues of $14.13 billion. La-Z-Boy — Shares slid 22% after the manufacturer of recliners posted earnings of 47 cents per share, excluding items, in the fiscal first quarter, missing the consensus estimate from analysts polled by FactSet of 53 cents. The company also gave weaker-than-expected guidance for current-quarter revenue. Alcon — U.S.-listed shares of the Swiss-based eyecare company shed 11%. Alcon's second-quarter revenue of $2.58 billion came in below the $2.62 billion expected from analysts polled by FactSet. The company also lowered its full-year revenue guidance. Toll Brothers — The luxury homebuilder slipped 1.6% following its weak full-year outlook. Toll Brothers, which reported a third-year earnings and revenue beat, expects to deliver 11,200 units versus its prior guidance of 11,200 to 11,600 units. It also guided for the average delivered price per home to come between $950,000 to $960,000, compared to its prior guidance of $945,000 to 965,000. Snowflake — The software stock rose 2.4% after being upgraded at Bank of America to buy from neutral. The bank expects its earnings, due next week, will be a catalyst for the stock and believes Snowflake will outperform long term thanks to artificial intelligence. Upstart — The online lender added 2.5% on the back of an upgrade at JPMorgan to overweight from neutral. The firm said the improved macroeconomic outlook is positive for seasoned fintech leaders and believes Upstart offers the best risk/reward. Gap — The clothing retail moved 2% lower as shares were downgraded to neutral from buy at Citi, which cited tariff pressures. Chip companies — Shares of some chips manufacturers moved lower following a Reuters report that the Trump administration is considering taking equity stakes in those companies that receive funding from the CHIPS Act. Micron sank 5%, while Intel , Taiwan Semiconductor Manufacturing and AMD were all down about 1%. — CNBC's Alex Harring, Sarah Min and Lisa Han contributed reporting.
